Chicago Atlantic acted as sole arranger and administrative agent in the closing of a $16.5 million senior secured term loan for Ocular Science, an affiliate of OSRX, a leading provider of compounded ophthalmic medications.
“Ocular Science is a leading biotech company focused on ophthalmology, guided by a patient-first philosophy and a commitment to manufacturing excellence. The company has built strong relationships with physicians and key opinion leaders nationwide,” Dino Colonna, partner at Chicago Atlantic, said. “Supported by favorable industry tailwinds, including an aging population and a differentiated value proposition that simplifies care delivery, we believe Ocular Science and OSRX are well positioned for continued growth.”
Anthony Sampietro, founder, president and CEO of Ocular Science and OSRX, said, “Our company was built by people who believe in doing the right thing for physicians and patients, even in the face of adversity and uncertainty. This capital strengthens our foundation, provides critical operating flexibility, and enables us to continue going the extra mile for our customers for many years to come.”
